Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Cilostazol
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 22 results found since Jan 2013.
Cilostazol for the Prevention of Acute Progressing Stroke: A Multicenter, Randomized Controlled Trial
Conclusions: Cilostazol failed to show a preventive effect against acute progressing stroke. However, the tendency to reduce progressing stroke and the results of stratified analyses may encourage additional studies to clarify the effect of cilostazol in the treatment of acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - April 1, 2013 Category: Neurology Authors: Hiroaki Shimizu, Teiji Tominaga, Akira Ogawa, Takamasa Kayama, Kazuo Mizoi, Kiyoshi Saito, Yasuo Terayama, Kuniaki Ogasawara, Etsuro Mori, Tohoku Acute Stroke Progressing Stroke Study Group Tags: Original Articles Source Type: research
Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study
Atherosclerosis is one of the main mechanisms of stroke and cardiovascular diseases and is associated with increased risk of recurrent stroke and cardiovascular events. Intima-medial thickness (IMT) is a well-known surrogate marker of atherosclerosis and has been used to predict stroke and cardiovascular events. However, the clinical significance of IMT and IMT change in stroke has not been investigated in well-designed studies. The PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage —Intima-Media Thickness (PICASSO-IMT) sub-study is designed to investigate the effects of...
Source: Journal of Stroke and Cerebrovascular Diseases - July 21, 2017 Category: Neurology Authors: Woo-Keun Seo, Yong Jae Kim, Juneyoung Lee, Sun U. Kwon, PICASSO Investigators Source Type: research
Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage
Cognitive impairment and dementia are common disabilities after stroke and are associated with increased risks of mortality and recurrent stroke. The prevention of dementia and preserving cognitive function are also important in stroke patients, but its strategy is not established yet. This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function.
Source: Journal of Stroke and Cerebrovascular Diseases - May 31, 2016 Category: Neurology Authors: Kyung-Ho Yu, Keun-Sik Hong, Mi-Sun Oh, Juneyoung Lee, Ji Sung Lee, Sun U. Kwon, PICASSO investigators Source Type: research
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis
Cilostazol has promise as an alternative to aspirin for secondary stroke prevention given its vasodilatory and anti-inflammatory properties in addition to platelet aggregation inhibition. We aimed to conduct a systematic review and meta-analysis to estimate the efficacy and safety of cilostazol compared to aspirin for stroke prevention in patients with previous stroke or transient ischemic attack (TIA).
Source: Journal of Stroke and Cerebrovascular Diseases - December 31, 2020 Category: Neurology Authors: Michelle P. Lin, James F. Meschia, Neethu Gopal, Kevin M. Barrett, Owen A. Ross, Nil üfer Ertekin-Taner, Thomas G. Brott Source Type: research
Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis
Antiplatelet therapy is recommended for patients who have experienced ischemic stroke. We performed a meta-analysis to compare the efficacy and safety of cilostazol with other antiplatelet therapies in patients with ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - March 24, 2015 Category: Neurology Authors: Liang Tan, Barnhart Margaret, John H. Zhang, Rong Hu, Yi Yin, Liu Cao, Hua Feng, Yanqi Zhang Source Type: research
The Effect of Acute Medication with Cilostazol, an Anti-platelet Drug, on the Outcome of Small Vessel Brain Infarction
In conclusion, cilostazol reduced the risk of early neurologic deterioration of patients with small vessel brain infarction. It is eagerly desired to conduct a large randomized control trial.
Source: Journal of Stroke and Cerebrovascular Diseases - February 10, 2014 Category: Neurology Authors: Taizen Nakase, Masahiro Sasaki, Akifumi Suzuki Tags: Original Articles Source Type: research
Antiplatelet Therapy as a Risk Factor for Microbleeds in Intracerebral Hemorrhage Patients: Analysis Using Specific Antiplatelet Agents
Conclusions: Attention to microbleed-positive patients is necessary for the safe use of aspirin in order to avoid antiplatelet-associated hemorrhages, but prospective studies are needed to verify our results.
Source: Journal of Stroke and Cerebrovascular Diseases - July 12, 2012 Category: Neurology Authors: Hiromitsu Naka, Eiichi Nomura, Jyuri Kitamura, Eiji Imamura, Shinichi Wakabayashi, Masayasu Matsumoto Tags: Original Articles Source Type: research
The Effect of Cilostazol on Carotid Intima–Media Thickness Progression in Patients with Symptomatic Intracranial Atherosclerotic Stenosis
Conclusion: Cilostazol has a beneficial effect in preventing the progression of CIMT in ischemic stroke patients.
Source: Journal of Stroke and Cerebrovascular Diseases - December 9, 2013 Category: Neurology Authors: Bum Joon Kim, Joung-Ho Rha, Seong Rae Kim, Dong-Eog Kim, Hahn Young Kim, Ju-Hun Lee, Hee-Joon Bae, Moon-Ku Han, Dong-Wha Kang, Disya Ratanakorn, Jong S. Kim, Sun U. Kwon Tags: Original Articles Source Type: research
Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis
Our previous trial acute dual study (ADS) reported that dual antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate of short-term neurological worsening in non-cardioembolic stroke patients. Present post-hoc analysis investigated whether the impact of combined cilostazol and aspirin differed among stroke subtypes and factors associated with neurological deterioration and/or stroke recurrence.
Source: Journal of Stroke and Cerebrovascular Diseases - December 2, 2020 Category: Neurology Authors: Junya Aoki, Yasuyuki Iguchi, Takao Urabe, Hiroshi Yamagami, Kenichi Todo, Shigeru Fujimoto, Koji Idomari, Nobuyuki Kaneko, Takeshi Iwanaga, Tadashi Terasaki, Ryota Tanaka, Nobuaki Yamamoto, Akira Tsujino, Koichi Nomura, Koji Abe, Masaaki Uno, Yasushi Okad Source Type: research
Prospective Registry of Carotid Artery Stenting in Japan—Investigation on Device and Antiplatelet for Carotid Artery Stenting
Background: Carotid artery stenting (CAS) is minimally invasive but may cause perioperative cerebral infarction associated with distal embolization. We conducted a multicenter prospective observational study on the onset of vascular events after CAS to find out the efficacy and safety of CAS in Japan and to investigate the effects of antiplatelet drugs administered before and after CAS on efficacy and safety of CAS.Methods: A total of 949 patients with cervical carotid artery stenosis were enrolled at 43 institutions in Japan; 934 who had undergone CAS with antiplatelet drugs and followed for 1 year were analyzed. Primary ...
Source: Journal of Stroke and Cerebrovascular Diseases - February 19, 2014 Category: Neurology Authors: Nobuyuki Sakai, Hiroshi Yamagami, Yoshihiro Matsubara, Masayuki Ezura, Akio Hyodo, Yuji Matsumaru, Shigeru Miyachi, Yasushi Okada, Tomoaki Terada, Hiroyoshi Yokoi, Mitusugu Nakamura, Yasushi Matsumoto, Chiaki Sakai, IDEALCAST Investigators Tags: Original Articles Source Type: research
Preventive Effect of Cilostazol on Pneumonia in Patients with Acute Cerebral Infarction
The antiplatelet drug cilostazol decreases the risk of ischemic stroke recurrence in patients with chronic cerebral infarction. Additionally, cilostazol reduces the occurrence of pneumonia in these patients. The purpose of this study was to investigate whether cilostazol is effective for preventing pneumonia in patients with acute cerebral infarction.
Source: Journal of Stroke and Cerebrovascular Diseases - May 11, 2018 Category: Neurology Authors: Yoshitsugu Nakamura, Hideto Nakajima, Fumiharu Kimura, Kiichi Unoda, Shigeki Arawaka Source Type: research
Efficacy of Cilostazol in Preventing Aspiration Pneumonia in Acute Cerebral Infarction
This retrospective study examined the effectiveness of cilostazol in preventing aspiration pneumonia in patients with acute cerebral infarction. The 189 subjects ranged in age from 31 to 95 years and included 57 with small-artery occlusion, 107 with large-artery atherothrombosis, and 25 with other disorders. Patients with cardiogenic cerebral embolism or preexisting pneumonia at the time of hospital admission were excluded from the analysis. Neurologic symptoms, cognitive function, and swallowing function were assessed at the first clinical examination, and the ability to perform activities of daily living was assessed at ...
Source: Journal of Stroke and Cerebrovascular Diseases - August 9, 2012 Category: Neurology Authors: Aiko Osawa, Shinichiro Maeshima, Norio Tanahashi Tags: Original Articles Source Type: research
Efficacy of Cilostazol in Prevention of Bradycardia during Carotid Artery Stenting
Conclusion: Use of cilostazol was associated with a lower incidence of IBc. Cilostazol may be a useful drug for the prevention of this complication.
Source: Journal of Stroke and Cerebrovascular Diseases - July 8, 2013 Category: Neurology Authors: Daizo Ishii, Tetsu Satow, Kenichi Murao, Kunihiro Nishimura, Koji Iihara Tags: Original Articles Source Type: research
Cilostazol Inhibits Platelet–Endothelial Cell Interaction in Murine Microvessels after Transient Bilateral Common Carotid Artery Occlusion
Background: The purpose of this study was to investigate the effects of cilostazol on platelet behavior (rolling and adhesion) in murine cerebral microvessels after transient bilateral carotid artery occlusion using intravital fluorescence microscopy.Methods: We used 41 C57BL/6J mice for the experiment. Fourteen mice were used as sham group (no ischemia and reperfusion, no medication); an ischemia (induced by 15-minute occlusion of bilateral common carotid arteries) and reperfusion (I/R) group (n = 17); and an I/R + cilostazol (I/R + CZ) group (receiving 30 mg/kg of cilostazol orally at 30 minutes before ischemia) ...
Source: Journal of Stroke and Cerebrovascular Diseases - October 16, 2013 Category: Neurology Authors: Takuya Fukuoka, Takeshi Hayashi, Makiko Hirayama, Hajime Maruyama, Norio Tanahashi Tags: Original Articles Source Type: research
